Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy

European Neurology

Volumn 41, Issue SUPPL. 1, 1999, Pages 20-26

  Freeman, Roy ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Clinical trials, phase I; Clinical trials, phase II; Clinical trials, phase III; Diabetic peripheral neuropathy; Drug evaluation; Human studies; Nerve growth factor

Indexed keywords

NEUROTROPHIN; RECOMBINANT NERVE GROWTH FACTOR;

ADULT; ALLODYNIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NERVE CELL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033047877     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052076     Document Type: Conference Paper

References (16)

1. Melton LJ III, Dyck PJ: Epidemiology; in Dyck PJ, Thomas PK (eds): Diabetic Peripheral Neuropathy. Philadelphia, Saunders, 1999, pp 239-250.
2. Ewing DJ, Clarke BF: Autonomic neuropathy: Its diagnosis and prognosis. Clin Endocrinol Metab 1986;15:855-888.
3. Thomas PK, Tomlinson DR: Diabetic and hypoglycemic neuropathy; in Dyck PJ, Thomas EH, Lambert RB, Thomas PK, Griffin JW, Low PA, Podulso JF (eds): Peripheral Neuropathy. Philadelphia, Saunders, 1993, pp 1219-1250.
4. Freeman R: Diabetic autonomic neuropathy - An overview; in Veves A (ed): Clinical Management of Diabetic Neuropathy. New Jersey, Humana Press, 1998, pp 181-208.
5. Ewing DJ, Campbell IW, Clarke BF: The natural history of diabetic autonomic neuropathy. Q J Med 1980;49:95-108.
6. O'Brien IA, McFadden JP, Corrall RJ: The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991;79:495-502.
7. Navarro X, Kennedy WR, Loewenson RB, Sutherland DE: Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes 1990;39:802-806.
8. Rathmann W, Ziegler D, Jahnke M, Haastert B, Gries FA: Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993;10:820-824.
9. Apfel SC: What are neurotrophic factors; in Apfel SC (ed): Clinical Applications of Neurotrophic Factors. Philadelphia, Lippincott-Raven, 1994, pp 1-54.
10. Apfel SC, Kessler JA: Neurotrophic factors in the therapy of peripheral neuropathy. Baillières Clin Neurol 1995;4:593-606.
11. Levi-Montalcini R: The nerve growth factor 35 years later. Science 1987;237:1154-1162.
12. Thoenen H, Barde YA: Physiology of nerve growth factor. Physiol Rev 1980;60:1284-1335.
13. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ: The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36:244-246.
14. Investigator Brochure: Recombinant human nerve growth factor (rhNGF): San Francisco, Genentech, and Basel, F. Hoffmann-LaRoche.
15. Dyck PJ, Peroutka S, Rask C, Burton E, Baker MK, Lehman KA, Gillen DA, Hokanson JL, O'Brien PC: Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997;48:501-505.
16. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, and the NGF Study Group: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.